Search research articles
Contact Us
Filters
Showing results (521-530 of 661) with videos related to
Page
of 67
Sort By:
Cancer Research
|
November 19, 2013
A novel EGFR isoform confers increased invasiveness to cancer cells
Min Zhou, Hai Wang, Keke Zhou, et al.
The Patient
|
November 28, 2017
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
Yi-Long Wu, Vera Hirsh, Lecia V Sequist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2015
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer
Caicun Zhou, Yi-Long Wu, Gongyan Chen, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 5, 2017
Evaluation of the VeriStrat<sup>®</sup> serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study
Shirish Gadgeel, Glenwood Goss, Jean-Charles Soria, et al.
Therapeutic Advances in Medical Oncology
|
November 25, 2022
An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)
Shun Lu, Ying Cheng, Jianying Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
Martin Schuler, Luis Paz-Ares, Lecia V Sequist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2023
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
Chong Kin Liam, Azura Rozila Ahmad, Te-Chun Hsia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2018
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer
Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, et al.
JAMA Oncology
|
April 1, 2021
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
Jie Wang, Shun Lu, Xinmin Yu, et al.
The Lancet. Oncology
|
July 10, 2015
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Jean-Charles Soria, Enriqueta Felip, Manuel Cobo, et al.
Page
of 67
Search research articles
Search
Showing results (521-530 of 661) with videos related to
Sort By:
Page
of 67
Cancer Research
|
November 19, 2013
A novel EGFR isoform confers increased invasiveness to cancer cells
Min Zhou, Hai Wang, Keke Zhou, et al.
The Patient
|
November 28, 2017
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
Yi-Long Wu, Vera Hirsh, Lecia V Sequist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2015
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer
Caicun Zhou, Yi-Long Wu, Gongyan Chen, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 5, 2017
Evaluation of the VeriStrat<sup>®</sup> serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study
Shirish Gadgeel, Glenwood Goss, Jean-Charles Soria, et al.
Therapeutic Advances in Medical Oncology
|
November 25, 2022
An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)
Shun Lu, Ying Cheng, Jianying Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
Martin Schuler, Luis Paz-Ares, Lecia V Sequist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2023
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
Chong Kin Liam, Azura Rozila Ahmad, Te-Chun Hsia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2018
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer
Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, et al.
JAMA Oncology
|
April 1, 2021
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
Jie Wang, Shun Lu, Xinmin Yu, et al.
The Lancet. Oncology
|
July 10, 2015
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Jean-Charles Soria, Enriqueta Felip, Manuel Cobo, et al.
Page
of 67